Dr. Reddy's launches Toripalimab in India
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
ORACEA is a trademark of Galderma Holdings, S.A.
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated